News

BlogsPosts
Press Release
RepliCel Life Sciences Appoints Head of Clinical and Regulatory Affairs
Appointment of Dr. Goessens-Rueck strengthens management team and fulfils commitment to promote female leadership in
BlogsPosts
Press Release
RepliCel Announces Federal Grant Funding for Collaboration with the University of Victoria, Canada
The National Sciences and Engineering Research Council of Canada has funded a University of Victoria
BlogsPosts
Press Release
RepliCel Life Sciences Appoints New Chief Financial Officer
VANCOUVER, Oct. 17, 2018 /CNW/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV:
BlogsPosts
Press Release
RepliCel CEO Provides Updated Outlook
Partnership and Investment Fuel Plans for Upcoming Advancements VANCOUVER, Oct. 15, 2018
BlogsPosts
As Seen In
Partnership Greenlighted for Canadian Biotech and Chinese Health Products Firm
RepliCel Life Sciences Inc. (RP:TSX.V; REPCF:OTCQB) and YOFOTO Health Industry Co.
BlogsPosts
As Seen In
9 Challenges Keeping Cell And Gene Therapy Executives Up At Night
Despite recent progress in regenerative medicine, cell and gene therapy executives
BlogsPosts
As Seen In
RepliCel's regenerative technology could take the "Polar Silk Road" to China
New opportunities are arising at every turn for the regenerative medicine
BlogsPosts
As Seen In
Regenerative Medicine Company's China Deal is 'Dramatically Transformational'
Echelon Wealth Partners detailed the terms and impact of this cell therapy developer's recent alliance
BlogsPosts
Press Release
RepliCel CEO Provides 2018 Shareholder Update
With a new Asian partnership and 2017 deliverables met, RepliCel is primed and ready for
BlogsPosts
Press Release
RepliCel Life Sciences Lands Commitment for Key Investment Partnership
YOFOTO (China) Health Industry Co. Ltd to Invest in Becoming RepliCel's Strategic Partner for Greater
BlogsPosts
As Seen In
From stem cells to revenue: Bringing regenerative medicine to the masses
RepliCel lands Asian partnership to optimize the development of its biotech
BlogsPosts
Press Release
RepliCel Life Sciences Successfully Closes Financing
Shareholders commit to non-brokered private placement in clear support of the Company’s partnership strategy
BlogsPosts
As Seen In
Why RepliCel May Be the Most Compelling Biotech Company to Watch in Canada
To read the brief and watch the interview provided by Market One Media Group as
BlogsPosts
As Seen In
RepliCel Life Sciences gets price target raise at Echelon Wealth Partners
To read the full article as it appears on Cantech Letters by Nick Waddell, click
BlogsPosts
Press Release
RepliCel Pursues Non-Diluting Grant Funding to Accelerate Value Creation and Commercialization
VANCOUVER, BC – March 7, 2017 – RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (“RepliCel”
BlogsPosts
Press Release
RepliCel Life Sciences Announces Re-pricing of Warrants
VANCOUVER, BC – March 6, 2017 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)
BlogsPosts
Press Release
RepliCel Life Sciences Announces Closing of Brokered and Non-brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION
BlogsPosts
Press Release
Replicel Life Sciences Inc. Announces Brokered Private Placement
VANCOUVER, BC – February 7, 2017 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)
BlogsPosts
As Seen In
Podcast: Replicel Life Sciences CEO Lee Buckler on global expansion
To listen to Podcast and View Transcript on Financial Post click here
BlogsPosts
As Seen In
Companies Flocking to Japan for Biotech Deals
To read the full article as it appears on The Life Sciences Report, click here.

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.